The RIPPLE AT-PLUS Study

Summary

Atrial tachycardia is a symptomatic arrhythmia, for which an effective treatment is a catheter ablation procedure. The goal of the Ripple AT-Plus study is to evaluate two methods of performing catheter ablation for atrial tachycardia. The main outcome assessed during the study is long-term recurrence of atrial tachycardia following the catheter ablation procedure.

Conditions

• Atrial Tachycardia

Interventions

PROCEDURE

Catheter ablation of atrial tachycardia: Ripple Mapping guided.

Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.

PROCEDURE

Catheter ablation of atrial tachycardia: Conventional mapping guided.

Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.

Sponsors & Collaborators

• Imperial College Healthcare NHS Trust

  collaborator OTHER

• Norfolk & Norwich University Hospital Trust

  collaborator UNKNOWN

• Nottingham University Hospitals NHS Trust

  collaborator OTHER

• University Hospitals Plymouth NHS Trust

  collaborator UNKNOWN

• Blackpool Teaching Hospitals NHS Trust

  collaborator UNKNOWN

• Cardiff & Vale UHB

  collaborator UNKNOWN

• University Hospitals Sussex NHS Foundation Trust

  collaborator UNKNOWN

• Liverpool Heart and Chest Hospital NHS Foundation Trust

  lead OTHER

Principal Investigators

• Vishal Luther, MBBS · Liverpool Heart & Chest Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-08-16

Primary Completion

2026-04-30

Completion

2026-04-30

Countries

• United Kingdom

Study Locations